Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment
This systematic review and meta-analysis evaluates the risk of new-onset inflammatory central nervous system diseases after tumor necrosis factor–inhibitor treatment for autoimmune disease.